Pr ecis: In melanoma, combining an antagonist of the immunosuppressive adenosine receptor A2A with BRAF and MEK inhibitors augments antitumor immunity to limit metastatic progression.
Pr ecis: These findings indicate that acquired resistance to T-cell-based immunotherapy that can occur in patients is not due to loss of target antigens or IFNg signaling, which appear to remain intact, but rather to other mechanisms yet to be identified. Pr ecis: This study shows how common downregulation of a stress response gene in liver cancer promotes metastatic progression, also providing a mechanistic rationale for new therapeutic approaches in this setting. Pr ecis: These findings provide a rationale for targeting the arginine methyltransferase Prmt1, a regulator of protein translation, as a strategy to eradicate cancer cells, which commonly display unique translation-dependent requirements.
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Targeting Histone Demethylases in MYC-Driven Neuroblastomas with Ciclopirox
Pr ecis: These findings provide new insights into epigenetic regulation of MYC function and suggest a novel pharmacologic basis to target histone demethylases as an indirect MYC-targeting approach for cancer therapy.
4639
Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity Carla Ríos-Luci, Sara García-Alonso, Elena Díaz-Rodríguez, Mercedes Nadal-Serrano, Joaquín Arribas, Alberto Ocaña, and Atanasio Pandiella Pr ecis: Drug resistance that arises invariably to cancer cell-targeted therapy also poses a challenge to antibodydrug conjugates, in this case through a novel mechanism involving alterations in the lysosome-based proteolytic activity.
4652
LSD1 Inhibitor T-3775440 Inhibits SCLC Cell Proliferation by Disrupting LSD1 Interactions with SNAG Domain Proteins INSM1 and GFI1B
Shinji Takagi, Yoshinori Ishikawa, Akio Mizutani, Shinji Iwasaki, Satoru Matsumoto, Yusuke Kamada, Toshiyuki Nomura, and Kazuhide Nakamura Pr ecis: These findings provide insights into how the interaction between LSD1 and SNAG domain proteins regulates transcription in neuroendocrine tumors and also offer a preclinical proof of concept for the therapeutic efficacy of targeting LSD1 in this setting. Pr ecis: This study shows how a signature of immune and desmoplastic stromal markers in an aggressive form of breast cancer can produce a simple ontology for gauging tumor heterogeneity and informing prognosis.
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Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis
